NEURO-ACTIVE (Effervescent Tablet)
COMPOSITION
Each tablet contains:
| Ingredients | mg per serving | % NRV* |
| Taurine | 250 mg | |
| Glucuronolactone | 150 mg | |
| Caffeine Anhydrous | 150 mg | |
| L-Theanine | 100 mg | |
| N-Acetyl L-Tyrosine (NALT) | 100 mg | |
| Inositol | 80 mg | |
| Bacopa Monnieri (Brahimi) (whole herb, as 50 mg of an extract standardized to 20 % Bacosides) |
50 mg | |
| L-α-Phosphatidyl-L-Serine (soyabean, as 50 mg of a powder standardized to 20 % Phosphatidylserine) |
50 mg | |
| Piper Nigrum (Black Pepper / Swartpeper) (fruit, as 5 mg of a 50:1 extract providing 250 mg dried herb equivalent) |
5 mg | |
| Vitamin B1 | 25 mg | 2083 % |
| Vitamin B2 | 5 mg | 385 % |
| Nicotinamide | 20 mg | 125 % |
| Vitamin B6 | 5 mg | 294 % |
| Vitamin B12 | 25 µg | 1042 % |
| Pantothenic acid | 4,6 mg | 91 % |
*% Nutrient Reference Values for individuals 4 years and older
Contains sweetener (30 mg sucralose; 700 mg isomalt)
PHARMACOLOGICAL CLASSIFICATION
Complementary Medicines
Category D
D. 33.7 Combination Product, Complementary Medicines: Discipline-specific medicine.
Multi-vitamin supplement. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Intended to only complement the health or supplement the diet.
PHARMACOLOGICAL ACTION
NOOLIT: NEURO-ACTIVE aids in diseases that interfere with memory and thinking (dementia), and in the muscle disease, myasthenia gravis.
INDICATIONS
NOOLIT: NEURO-ACTIVE is indicated to:
- aid with cognitive function and impaired concentration in adults.
temporarily promotes alertness and wakefulness - temporarily assists to relieve fatigue
- temporarily assists to increase mental activity
- energy metabolism
- aid in the metabolism of
- carbohydrates, fats and proteins
- contribute to tissue formation
the maintenance of good health.
CONTRA-INDICATIONS
Patients who have shown hypersensitivity to this product or any of its components. Hypersensitivity/allergy, in which case, discontinue use.
Pregnant women or women of childbearing potential.
Not to be consumed by children.
WARNINGS AND SPECIAL PRECAUTIONS
CONTAINS CAFFEINE.
Identifying and contextualizing the amount of caffeine contained in the product per dosage
unit. Contains 150 mg caffeine per effervescent tablet. For adults only.
Consult a registered healthcare professional if you are taking any other medicine or have been diagnosed with a chronic condition. Use of caffeine may result in sleep deprivation. Limit the use of caffeine-containing products (including tea and coffee) when taking this product.
Total caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding.
DO NOT EXCEED THE MAXIMUM RECOMMENDED INTAKE OF 2 TABLETS PER DAY.
Effects on ability to drive and use machines: No data available.
INTERACTIONS
No interaction studies have been performed.
PREGNANCY AND LACTATION
The safety of this product in human pregnancy has not been established.
Consult a relevant health care provider prior to use if you are pregnant or breastfeeding.
DOSAGE AND DIRECTIONS FOR USE
Adults: Dissolve 1 tablet in a glass of water, and take once or twice daily for the improvement of cognitive function and impaired concentration.
DO NOT EXCEED 2 TABLETS PER DAY.
SIDE-EFFECTS
Any nausea (probably due to a secondary dopaminergic activation) may require dosage reduction.
Digestive system: gastritis, gastrointestinal disease.
Central Nervous System: drowsiness, insomnia, nervousness, convulsion, hyperkinesia.
KNOWN SYMPTOMS OF OVERDOSE AND PARTICULARS OF ITS TREATMENT
At doses of more than 600 mg per day, caffeine may cause anxiety, tachycardia (rapid heart rate), palpitations, insomnia, restlessness, nervousness, tremor and headache.
IDENTIFICATION
White bovine gelatine capsule
PRESENTATION
NOOLIT: NEURO-ACTIVE capsules are packaged in a white pet bottle with heat seal
and a white safety screw top lid.
STORAGE INSTRUCTIONS
Store in a cool, dry place below 25 °C.
KEEP OUT OF REACH OF CHILDREN.
REGISTRATION NUMBER
To be allocated
NAME AND BUSINESS ADDRESS OF THE APPLICANT
XS PHARMA (Pty) Ltd
The Innovation Hub
1 Mark Shuttleworth St
Lynwood
Pretoria
0087
DATE OF PUBLICATION OF THE PACKAGE INSERT
October 2021
CATEGORY D
D. 33.7 Combination Product, Complementary Medicines: Discipline-specific medicine.
This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Intended to only complement the health or supplement the diet.